CODING THEFUTURE OFBIOLOGY
A venture capital firm capturing the golden age of bio-convergence and healthcare AI — backing the architects of humanity's next chapter, from seed to Series A.
Managed by Blackforest Global Management · MAS CMS 101232
Based in Singapore · Global Origination
Alpha at the Intersection
Pure software funds don't understand biological risk. Pure clinical funds struggle to underwrite AI. Telomere operates exclusively in the white space between these two domains.
Biotech
Engineering Biology at the Molecular Level
We invest in platforms that reprogram biological systems — from gene editing to synthetic biology. The convergence of AI and wet-lab science is compressing decades of R&D into months.
Medtech
Precision Instruments for Precision Medicine
Next-generation diagnostics, robotic surgery, and implantable devices are transforming clinical outcomes. We back founders building the infrastructure of modern healthcare delivery.
Digital Health
Software Eating Healthcare
AI-driven clinical decision support, remote patient monitoring, and healthcare SaaS platforms that replace labor-intensive care with scalable, technology-driven products.
TechBio
Computation-First Drug Discovery
Machine learning models now predict protein structures and identify clinical biomarkers with unprecedented accuracy. TechBio represents the full stack integration of silicon and cell.
Precision Capital for Asymmetric Returns
A Generational Entry Point
Seed/Series A valuations have rationalized to historic averages. Large pharma faces massive patent cliffs between 2026–2028 and must acquire de-risked early-stage assets, providing guaranteed exit velocity for our portfolio companies.
Portfolio Construction
- 15–20 Core Positions
- 50% Reserved for Follow-ons
- Seed & Series A Focus
- 8–12% Target Ownership
Global Origination
- US / EU / Israel Source Markets
- China & Taiwan Bio-Hardware
- Singapore Safe Harbor & IP
- APAC Clinical Trial Access
Return Architecture
- No Unicorn Dependency
- $300M–$500M Mid-Market Exits
- 10% Stake → 60–100% Fund Return
- Pharma M&A Tailwind 2026–28
Risk Mitigation
- Heavy Weight Non-FDA Assets
- SaaS Digital Health ARR Base
- Technical DD by PhD/MD Board
- Institutional Compliance Day-1
The Living Lab Record
We don't just deploy capital — we architect the bridge between breakthrough science and commercial viability.
Rybodyn
Seed · $10MUses its RyboCypher™ AI platform to decode the "Dark Proteome" for cancer immunotherapy. Represents the fund's ability to win institutional bio-convergence deals.
Thesis Link: TechBio → OncologyPipeline Asset 1
Series A · Deep DiligenceFull-stack AI-driven platform accelerating pre-clinical to IND timelines by 60%. Currently in deep diligence in data room with strong syndicate interest.
Thesis Link: TechBio → Drug DiscoveryPipeline Asset 2
Seed · Soft-CircledAI-powered diagnostic platform providing real-time clinical decision support. Non-FDA regulated, recurring revenue model with rapid enterprise adoption.
Thesis Link: Digital Health → DiagnosticsCancerAsia.ai
As co-founders, the GPs built an AI-driven ecosystem to support cancer patients. This provides Telomere with a proprietary lens to evaluate healthcare AI startups. If an algorithm doesn't practically reduce friction for the patient or provider, Telomere won't invest.
Mission-Driven GPs Who Understand Clinical Realities
Companies We've Backed
Live positions that demonstrate our thesis in action.
GP Personal InvestmentSeedRybodyn
Computation-First Drug Discovery
Uses its RyboCypher™ AI platform to decode the "Dark Proteome" for cancer immunotherapy. A personal investment by the GP, reflecting the team's ability to source and win institutional bio-convergence deals.
Thesis Link: TechBio → Oncology
Venture StudioPillar Digital Health Ventures
Telomere's in-house venture studio — an engine for deal flow creation that originates, validates, and incubates healthcare AI and bio-convergence companies before they reach the market.
From Thesis to Portfolio
Pillar operates as the origination arm of Telomere Ventures. By building companies from first principles, it generates a proprietary pipeline of high-conviction deals — giving the fund early access, structural alignment, and a true information edge that external deal flow cannot match.
Originate
Scan source markets for unmet clinical needs and emerging bio-convergence signals before they become deal flow.
Validate
Stress-test thesis, technology, and clinical fit with PhD/MD advisors — de-risking ideas before they reach the fund.
Incubate
Co-build founding teams, refine product, and structure companies for institutional-grade capital from day one.
Integrate
Hand off validated, incubated companies to Telomere Ventures as prioritized, high-conviction investment opportunities.
Dual Expertise as Investors & Operators
Lance QuekMSID
General Partner
Value investor and venture operator with a proven track record in bio-convergence deals. Participated in the Seed investment in Rybodyn. Brings deep global deal flow networks spanning US, EU, Israel, China and Taiwan.
Jo Lee
General Partner
Healthcare operator and investor with deep expertise in clinical workflows and patient engagement. Co-founded CancerAsia.ai, an AI-driven cancer patient support ecosystem — giving Telomere a proprietary lens to evaluate healthcare AI. If it doesn't reduce real clinical friction, we won't invest.
Institutional-Grade Technical DD
PhDs, MDs, and bio-informaticians validate molecular pathways and clinical trial designs, allowing the GPs to focus entirely on commercialization and scaling.
Day-1 Institutional Infrastructure
Telomere is fully backed and managed by Blackforest Global Management (MAS CMS 101232), providing institutional compliance, audit, and reporting from inception.
Every Dollar Deployed Improves Lives
By accelerating drug discovery and expanding patient access via AI, every dollar deployed actively works toward improving global health outcomes.
The aging population demands a paradigm shift from labor-intensive care to technology-driven solutions.
AI-powered platforms are compressing decades of pharmaceutical R&D into months.
Massive M&A activity as pharma must acquire de-risked early-stage assets.
The global pharmaceutical market is accelerating into a new era of engineered precision.
Let's Build the Future of Healthcare
If you're a founder building at the frontier of bio-convergence and healthcare AI, we'd like to hear from you.